LTRN: Lantern Pharma Inc. Stock

by  •  • Comments Off on LTRN: Lantern Pharma Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 37.64
Enterprise Value ($M) 30.13
Book Value ($M) 21.19
Book Value / Share 1.96
Price / Book 1.78
NCAV ($M) 20.86
NCAV / Share 1.93
Price / NCAV 1.80

Profitability (mra)
Return on Invested Capital (ROIC) -0.97
Return on Assets (ROA) -0.52
Return on Equity (ROE) -0.58

Liquidity (mrq)
Quick Ratio 5.83
Current Ratio 5.83

Balance Sheet (mrq) ($M)
Current Assets 25.25
Assets 25.57
Liabilities 4.38
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -22.22
Net Income -20.78

Cash Flow Statement (mra) ($M)
Cash From Operations -17.81
Cash from Investing 3.37
Cash from Financing 0.07

(click for more detail)
Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUA
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 1,045 8,010 13.05
2025-04-16 2,484 24,176 10.27
2025-04-15 20,531 81,982 25.04
2025-04-14 18,106 46,565 38.88

(click for more detail)

Similar Companies
LPTX – Leap Therapeutics, Inc. LQDA – Liquidia Corporation
LSTA – Lisata Therapeutics, Inc. MBIO – Mustang Bio, Inc.
MBRX – Moleculin Biotech, Inc.


Financial data and stock pages provided by
Fintel.io